AG真人官方

Anson Funds Management LP and related entities filed Amendment No. 6 (exit filing) to their Schedule 13D on Nano Dimension Ltd. (NASDAQ: NNDM) dated 11 July 2025 and signed 14 July 2025.

The reporting group 鈥� Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., and individuals Tony Moore, Amin Nathoo and Moez Kassam 鈥� now report beneficial ownership of 9,057,952 ordinary shares (represented by the same number of ADSs), equivalent to 4.2 % of the 217,283,476 shares outstanding as of 30 April 2025. Because the ownership has fallen below the 5 % threshold, this amendment constitutes their final 鈥渆xit鈥� filing.

Key details:

• Voting / dispositive power: 0 shares sole; 9,057,952 shares shared (both voting and dispositive).
• Acquisition cost: approximately $24.87 million of fund working capital (exclusive of commissions) was used to purchase the ADSs through open-market transactions.
• Derivative exposure: The funds no longer hold the derivative agreements disclosed in the previous amendment.

The filing amends and restates Items 3 and 5(a)-(c), (e), and supplements Item 6 of the original Schedule 13D first filed 10 March 2023.

Schedule 13D/A Amendment No. 5 discloses that a group of related entities and individuals led by Anson Funds Management LP now beneficially owns 16,361,433 ordinary shares of Nano Dimension Ltd. ("NNDM"), represented by the same number of American Depositary Shares (ADSs). This stake represents 7.5 % of the company鈥檚 217,283,476 shares outstanding as reported on 30 April 2025.

The reporting group comprises Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., and principals Tony Moore, Amin Nathoo and Moez Kassam. The investors state that approximately US $25.36 million of fund working capital was used to accumulate the position.

Derivative exposure. Item 6 reveals that the funds have entered into cash-settled swap agreements providing short economic exposure to 4,247,231 ADSs, equivalent to a notional 1.95 % of outstanding shares. These swaps confer no voting or dispositive power over the referenced shares.

Voting & dispositive power. The group reports zero sole voting/dispositive power and shared voting and dispositive power over all 16.36 million shares, indicating coordinated control.

• Date triggering filing: 26 Jun 2025
  
• Filing date / signatures: 03 Jul 2025
  
• Filing purpose: Restates Items 3 and 5, supplements Item 6 of the original Schedule 13D filed 10 Mar 2023.

This amendment mainly updates ownership totals, funding source, and disclosure of new short derivative positions. No other contracts or arrangements with respect to NNDM securities are reported.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) filed a Form 8-K reporting two key developments. Under Item 1.01 the Company exercised its contractual right, effective June 27 2025, to terminate the Licensing Agreement with Ocuphire Pharma, Inc. (now Opus Genetics) that had originally been signed on June 16 2021. The filing does not disclose termination fees, financial considerations, or specific reasons for the decision.

Item 7.01 references a press release dated July 1 2025 (Exhibit 99.1) announcing a "strategic portfolio review and pipeline realignment" intended to maximize shareholder value. No operational details, timelines, or updated guidance are included in the 8-K; the press release itself is incorporated by reference but not reproduced in the filing.

The document lists three exhibits鈥�10.1 Termination Agreement, 99.1 Press Release, and 104 iXBRL cover page鈥攁nd contains no pro-forma financial statements, earnings data, or revised forecasts. As such, investors are informed that Processa has ended one partnered program and is evaluating its development priorities, but the quantitative impact on the Company鈥檚 pipeline, cash runway, or future milestones remains undisclosed.

NVE Corporation鈥檚 Definitive Additional Proxy Materials (DEFA14A) include a shareholder letter from CEO Daniel A. Baker highlighting fiscal-year 2025 performance, strategic investments, and capital-return priorities.

Operational performance. Management reports 鈥渟trong earnings鈥� for FY-2025 despite a full-year revenue decline, noting sequential growth in the most recent quarter and resilience during industry weakness. Total Shareholder Return for the past three fiscal years reached 39%.

Innovation and R&D. R&D spending increased 33% year-over-year to support new product lines. Product launches during the year included high-sensitivity ultraminiature sensors, a new rotation sensor, wafer-level chip-scale sensors, advanced position sensors, and accompanying evaluation boards.

Capacity expansion. The company completed a 鈥渕ultimillion-dollar鈥� facility expansion that adds wafer-level chip-scale manufacturing, designed to improve self-sufficiency and reduce outsourced packaging costs.

Strategic partnerships. NVE extended its partnership agreement with Abbott Laboratories for medical-device applications, reinforcing its presence in high-reliability healthcare markets.

Capital allocation. Since initiating dividends a decade ago, NVE has returned more than $200 million in cash鈥攅quivalent to over $42 per share. Management reiterates its commitment to 鈥済enerous dividends鈥� as part of its shareholder-value strategy.

Positioning. Inventory investments, niche high-value products, and expanded manufacturing capacity position the company to 鈥渢hrive in a fluid international trade environment鈥� and to capture growth from industrial IoT and medical-device markets.

The letter contains forward-looking statements subject to risks detailed in NVE鈥檚 Form 10-K for the year ended 31 March 2025.

Form 144 Notice filed by Nano Dimension Ltd (NASDAQ: NNDM) on June 28, 2025, regarding a proposed sale of securities by Officer Zvi Peled. The filing details the following key information:

• Proposed sale of 38,542 ordinary shares with aggregate market value of $55,500.48
• Shares were originally acquired through Employee Stock Option Plan on May 28, 2020
• Sale to be executed through Oppenheimer & Co. Inc. on NASDAQ
• Total shares outstanding: 215,776,705
• Recent prior sale: 12,676 shares sold on June 25, 2025, for gross proceeds of $17,999.92

The filing includes standard Rule 144 representations that the seller has no knowledge of undisclosed material adverse information regarding the company's operations. Payment for the original acquisition will be made in cash upon exercise of options.

Nano Dimension has filed a Form 144 notice for a proposed sale of securities, indicating an insider's intent to sell company shares. The filing details plans to sell 12,676 ordinary shares with an aggregate market value of $17,999.92 through broker Oppenheimer & Co.

Key transaction details:

• Shares were originally acquired through an Employee Stock Option Plan on May 28, 2020
• Planned execution date: June 25, 2025
• Trading venue: NASDAQ
• Payment method: Cash upon exercise
• Total shares outstanding: 215,776,705

The filing indicates no other securities were sold by the same person during the past 3 months. This Form 144 represents approximately 0.006% of total shares outstanding, suggesting a relatively minor insider transaction.